Meeting
2021 ASCO Annual Meeting
Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).
Authors
Christopher James Walker
Karyopharm Therapeutics Inc, Newton, MA
Christopher James Walker , Shirong Li , Yi Chai , Jatin J. Shah , Sharon Shacham , Suzanne Lentzsch , Yosef Landesman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03110562
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8027)
DOI
10.1200/JCO.2021.39.15_suppl.8027
Abstract #
8027
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.
First Author: Xavier Leleu
Poster
2021 ASCO Annual Meeting
Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.
First Author: Thierry Facon
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2019 ASCO Annual Meeting
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).
First Author: Paul G. Richardson